JP2018528985A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528985A5
JP2018528985A5 JP2018533979A JP2018533979A JP2018528985A5 JP 2018528985 A5 JP2018528985 A5 JP 2018528985A5 JP 2018533979 A JP2018533979 A JP 2018533979A JP 2018533979 A JP2018533979 A JP 2018533979A JP 2018528985 A5 JP2018528985 A5 JP 2018528985A5
Authority
JP
Japan
Prior art keywords
liquid composition
epilepsy
oral liquid
purity
cannabidiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018533979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528985A (ja
Filing date
Publication date
Priority claimed from BR102015024165A external-priority patent/BR102015024165A2/pt
Application filed filed Critical
Publication of JP2018528985A publication Critical patent/JP2018528985A/ja
Publication of JP2018528985A5 publication Critical patent/JP2018528985A5/ja
Pending legal-status Critical Current

Links

JP2018533979A 2015-09-18 2016-09-16 カンナビノイドを含む経口医薬組成物、その調製及び使用のための方法 Pending JP2018528985A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR102015024165A BR102015024165A2 (pt) 2015-09-18 2015-09-18 composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
BRBR102015024165-8 2015-09-18
PCT/BR2016/050231 WO2017045053A1 (pt) 2015-09-18 2016-09-16 Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso

Publications (2)

Publication Number Publication Date
JP2018528985A JP2018528985A (ja) 2018-10-04
JP2018528985A5 true JP2018528985A5 (enExample) 2021-02-04

Family

ID=58288018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018533979A Pending JP2018528985A (ja) 2015-09-18 2016-09-16 カンナビノイドを含む経口医薬組成物、その調製及び使用のための方法

Country Status (8)

Country Link
US (1) US20180264121A1 (enExample)
EP (1) EP3351242A4 (enExample)
JP (1) JP2018528985A (enExample)
CN (1) CN108366988A (enExample)
AU (1) AU2016322148A1 (enExample)
BR (2) BR102015024165A2 (enExample)
CA (1) CA2998739A1 (enExample)
WO (1) WO2017045053A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658137A1 (en) * 2017-07-27 2020-06-03 Shaaban, Basil Adil Cannabinoid composition having an optimized fatty acid excipient profile
CA3079723A1 (en) * 2017-10-16 2019-04-25 Joshua Raderman Cannabinoid formulations and methods including the antioxidant c60
CN111971041A (zh) 2018-02-07 2020-11-20 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、组合物、方法及其用途
BR102018002843A2 (pt) 2018-02-09 2019-08-27 Prati, Donaduzzi & Cia Ltda composição farmacêutica e uso da mesma
CN112384212A (zh) 2018-05-03 2021-02-19 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、其组合物、方法和用途
US20220304963A1 (en) * 2018-07-27 2022-09-29 Basil Shaaban Composition having an optimized fatty acid excipient profile
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
US20210186870A1 (en) * 2018-08-27 2021-06-24 Emerald Health Therapeutics Canada Inc. Improved cannabinoid bioavailability
CN108968071A (zh) * 2018-09-26 2018-12-11 江西中医药大学 代代花和火麻仁组合物在制备改善记忆力减退或治疗抑郁症药物或保健功能饮料中的应用
BR112021011509A2 (pt) 2018-12-14 2021-08-31 Natural Extraction Systems, LLC Composições e métodos relativos a moléculas de canabinoide aniônicas
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
CA3040547C (en) * 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
DK3826630T3 (da) * 2019-07-21 2022-09-26 Scf Pharma Inc Sammensætninger af cannabinoider med polyumættede fedtsyremonoglycerider og anvendelser heraf
AU2020326738A1 (en) * 2019-08-08 2022-03-03 Purcann Pharma Inc. Oral formulations of cannabis extracts and methods of making same
WO2021041637A1 (en) * 2019-08-28 2021-03-04 Natural Extraction Systems, LLC Compositions comprising cannabinoid ions dissolving in glycerol
MX2022002548A (es) * 2019-09-09 2022-03-22 Cardiol Therapeutics Inc Composiciones medicinales estables de cannabidiol.
CN113694049B (zh) * 2020-05-21 2022-11-22 汉义生物科技(北京)有限公司 大麻素类化合物及其在治疗帕金森症中的应用
CN111603443B (zh) * 2020-06-12 2022-06-28 苏州旺山旺水生物医药有限公司 一种稳定的cbd组合物及其应用
US12349706B2 (en) 2020-07-31 2025-07-08 Natural Extraction Systems, LLC Compositions and methods related to excipients and cannabinoid formulations
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
JP7837051B2 (ja) * 2021-09-08 2026-03-30 株式会社東洋新薬 経口組成物
EP4601629A1 (en) * 2022-10-12 2025-08-20 Leiutis Pharmaceuticals LLP Novel liquid oral formulations of cannabidiol
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof
EP4518851A4 (en) * 2023-07-24 2025-07-30 Poviva Corp Compositions and methods for treating epilepsy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004893A1 (en) * 1990-09-13 1992-04-02 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20070129340A1 (en) * 2004-02-06 2007-06-07 Chugai Seiyaku Kabushiki Kaisha Ed-71 preparation
US20140357708A1 (en) * 2005-11-07 2014-12-04 Murty Pharmaceuticals, Inc. Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
ES2581212T3 (es) * 2005-11-07 2016-09-02 Murty Pharmaceuticals, Inc. Administración mejorada de tetahidrocannabinol
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
US8222292B2 (en) * 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
EP2642982A2 (en) * 2010-11-22 2013-10-02 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US20150132400A1 (en) * 2012-05-07 2015-05-14 Echo Pharmaceuticals B.V. Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
US9763991B2 (en) * 2013-06-13 2017-09-19 Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
CA2950424C (en) * 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
GB2542155B (en) * 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders

Similar Documents

Publication Publication Date Title
CN103635189B (zh) 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
SG10201903474PA (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
JP2016528301A5 (enExample)
JP2014517050A5 (enExample)
JP2018513107A5 (enExample)
RU2015143466A (ru) Нейроактивные стероиды и способы их применения
JP2016513717A5 (enExample)
JP2018021046A5 (enExample)
JP2014502641A5 (enExample)
JP2015536307A5 (enExample)
JP2016540749A5 (enExample)
JP2016027060A5 (enExample)
JP2016515628A5 (enExample)
JP2015524423A5 (enExample)
JP2017526747A5 (enExample)
JP2015500223A5 (enExample)
EP4233913A3 (en) Improved bromocriptine formulations
ZA201704327B (en) Methods and compositions for treating brain diseases
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
JP2016505039A5 (enExample)
JP2014522836A (ja) 併用療法
JP2017502069A5 (enExample)
JP2017536410A5 (enExample)
CN104161723A (zh) 一种地克珠利溶液及其制备方法
PH12019502322A1 (en) Smectite suspension liqiud composition and method for preparing same